Form 4: Sangamo Therapeutics Executive Sells Shares for Tax Withholding

Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, disposed of 31,866 shares of common stock to cover tax obligations related to a restricted stock unit vesting.

Summary

• Nathalie Dubois-Stringfellow, SVP-Chief Development Officer at Sangamo Therapeutics, Inc. (SGMO), disposed of 31,866 shares of common stock.
• The disposition occurred on July 22, 2025, at a price of $0.4798 per share.
• This transaction was solely for mandatory tax withholding purposes related to the vesting of a restricted stock unit (RSU) grant.
• The shares were surrendered to the Issuer based on the closing stock price on the vesting date.
• This was not a discretionary trade by the Reporting Person.
• Following this transaction, Nathalie Dubois-Stringfellow beneficially owns 767,881 shares of Sangamo Therapeutics common stock.
• The beneficial ownership includes shares from various RSU grants with future vesting schedules.

Sentiment

Score: 5

Explanation: The filing reports a routine, non-discretionary transaction for tax withholding purposes related to RSU vesting. This is a neutral event that does not indicate positive or negative sentiment regarding the company's performance or outlook.

Positives

• The transaction is a routine tax withholding event, not a discretionary sale, which typically indicates no negative sentiment from the insider regarding the company's future prospects.
• The executive continues to hold a substantial number of shares (767,881), indicating continued alignment with shareholder interests.

Future Outlook

The filing details future vesting schedules for various Restricted Stock Unit (RSU) grants held by the SVP-Chief Development Officer. These include 178,125 shares from a January 22, 2024 RSU grant vesting quarterly through January 22, 2026; 15,030 shares from a February 24, 2023 RSU grant vesting quarterly through February 24, 2026; and 120,000 shares from a February 25, 2025 RSU grant, with one-fourth vesting on February 25, 2026, and the remainder in 8 successive equal quarterly installments thereafter. All vesting is contingent on continuous service and subject to acceleration provisions of the 2018 Equity Incentive Plan.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, specifically related to executive compensation and tax obligations. It does not provide broader industry context or strategic updates for Sangamo Therapeutics, which operates in the biotechnology sector focusing on genomic medicine.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in executive confidence or company fundamentals. The executive retains a significant stake.
• Employees: No direct impact indicated.
• Customers: No direct impact indicated.
• Suppliers: No direct impact indicated.
• Creditors: No direct impact indicated.

Next Steps

• Continued vesting of 178,125 shares from the January 22, 2024 RSU grant in successive equal quarterly installments through January 22, 2026.
• Continued vesting of 15,030 shares from the February 24, 2023 RSU grant in successive equal quarterly installments through February 24, 2026.
• Vesting of 120,000 shares from the February 25, 2025 RSU grant, with one-fourth vesting on February 25, 2026, and the remainder in 8 successive equal quarterly installments thereafter.

Key Dates

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Tax Withholding, Executive Compensation, Nathalie Dubois-Stringfellow, Biotechnology, Pharmaceuticals